Global CNS Therapeutics Market 2018-2022

Global CNS Therapeutics Industry Overview

Technavio’s analysts have identified the increasing prevalence of mental illness to be one of the major factors driving market growth. 20% of the US population suffered from mental illness in 2017. According to the Centers for Disease Control and Prevention (CDC), most of these disorders coexist with other diseases such as diabetes, cardiovascular disease, and obesity. Rise in the hospital visits has been observed due to the increasing prevalence of mental disorders. The availability of effective therapeutics is required to tackle mental disorders and reduce the number of deaths associated with them.  

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report. 

Companies covered

With the presence of a considerable number of companies, the CNS therapeutics market appears to be moderately fragmented. The central nervous system (CNS) therapeutic market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

The report offers a complete analysis of a number of companies including:

• Eli Lilly
• F. Hoffmann-La Roche
• Johnson & Johnson
• Merck
• Novartis

CNS therapeutics market growth based on geographic regions

• Americas
• APAC
• EMEA

Our analysts have predicted that in terms of geographic regions, the central nervous system (CNS) therapeutic market will witness considerable growth in the Americas during the next few years. This region will be the major contributor to the growth of the market due to the increased awareness about the benefits of CNS therapeutics for mental illnesses.

CNS therapeutics market growth based on end-user

• MHDs
• NDDs

The MHDs segment accounted for the major share of the central nervous system (CNS) therapeutic market during 2017. MHDs include substance use disorder, psychoses, depression, bipolar disorder, and eating disorders. With the advent of a range of MHDs, the awareness about these disorders have increased. This increases the demand for their required treatments.

Key highlights of the global CNS therapeutics market for the forecast years 2018-2022:

• CAGR of the market during the forecast period 2018-2022
• Detailed information on factors that will accelerate the growth of the CNS therapeutics market during the next five years
• Precise estimation of the global CNS therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• Growth of the CNS therapeutics industry across various geographies such as the Americas, APAC, and EMEA
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive information about factors that will challenge the growth of the companies in the CNS therapeutics market.

Get more value with Technavio’s INSIGHTS subscription platform! Gain easy access to all of Technavio’s reports, along with on-demand services. Try the demo

This market research report analyzes the market outlook and provides a list of key trends, drivers, and challenges that are anticipated to impact the global CNS therapeutics market and its stakeholders over the forecast years.

Technavio’s market research analysts have also considered how the performance of other related markets in the vertical will impact the size of this market till 2022. One of the markets most likely to influence the growth of the CNS therapeutics market over the coming years is the central nervous system disorders therapeutics market.

Technavio also provides customized reports based on the specific requirements our clients.